- Home
- S vs ROIV Comparison
S vs ROIV Comparison
Compare S & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- S
- ROIV
- Stock Information
- Founded
- S 2013
- ROIV 2014
- Country
- S United States
- ROIV United Kingdom
- Employees
- S N/A
- ROIV N/A
- Industry
- S EDP Services
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- S Technology
- ROIV Health Care
- Exchange
- S Nasdaq
- ROIV Nasdaq
- Market Cap
- S 8.7B
- ROIV 8.4B
- IPO Year
- S 2021
- ROIV N/A
- Fundamental
- Price
- S $22.12
- ROIV $10.68
- Analyst Decision
- S Buy
- ROIV Strong Buy
- Analyst Count
- S 29
- ROIV 8
- Target Price
- S $29.41
- ROIV $17.93
- AVG Volume (30 Days)
- S 3.7M
- ROIV 3.8M
- Earning Date
- S 03-12-2025
- ROIV 02-10-2025
- Dividend Yield
- S N/A
- ROIV N/A
- EPS Growth
- S N/A
- ROIV N/A
- EPS
- S N/A
- ROIV N/A
- Revenue
- S $770,115,000.00
- ROIV $122,585,000.00
- Revenue This Year
- S $34.37
- ROIV $15.98
- Revenue Next Year
- S $25.68
- ROIV N/A
- P/E Ratio
- S N/A
- ROIV N/A
- Revenue Growth
- S 34.38
- ROIV 140.04
- 52 Week Low
- S $14.33
- ROIV $9.76
- 52 Week High
- S $29.29
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- S 37.29
- ROIV 42.58
- Support Level
- S $21.92
- ROIV $10.33
- Resistance Level
- S $25.24
- ROIV $10.86
- Average True Range (ATR)
- S 0.83
- ROIV 0.27
- MACD
- S -0.19
- ROIV 0.02
- Stochastic Oscillator
- S 6.02
- ROIV 29.96
About S SentinelOne Inc.
SentinelOne is a cloud-based cybersecurity company specializing in endpoint protection. SentinelOne's primary offering is its Singularity platform that offers a single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The California-based firm was founded in 2013 and went public in 2021.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.